Synergistic effects of mTOR inhibitors with VEGFR3 inhibitors on the interaction between TSC2-mutated cells and lymphatic endothelial cells
Science China Life Sciences · 2025
DOI: 10.1007/s11427-024-2760-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science China Life Sciences, 2025. Verfasst von Hanghang Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, …. Hauptthemen laut MEDLINE: Tuberous Sclerosis Complex 2 Protein, Endothelial Cells, Vascular Endothelial Growth Factor Receptor-3, Lymphangioleiomyomatosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Abstract (Originalsprache)
Lymphangioleiomyomatosis (LAM) is a rare neoplastic disease affecting the lung, kidney, and lymphatic system with a molecular mechanism of tuberous sclerosis complex 2 (TSC2) mutations. Vascular endothelial growth factor D (VEGF-D), a ligand for vascular endothelial growth factor receptor 3 (VEGFR3), is a diagnostic biomarker of LAM and is associated with lymphatic circulation abnormalities. This study explored the interaction between LAM cells and lymphatic endothelial cells (LECs) and the effects of rapamycin on this interaction, which may help to identify new targets for LAM treatment. This study used direct and indirect cocultures of TSC2-null cells and LECs. The xenograft model was applied to explore the therapeutic feasibility. Single-cell sequencing revealed increased LECs in the lungs of LAM patients through activation of pathways involved in lymphangiogenesis. TSC2-null cells attracted LECs and promoted tube formation. VEGF-D/VEGFR3 was a key mediator of the above interaction. Rapamycin can directly inhibit recruitment but not the tube formation of LECs in vitro. The combination of rapamycin with VEGFR3 inhibitors not only enhanced the effect of rapamycin but also inhibited lymphatic related manifestations including the tube formation and the lymphatic metastasis. Our findings demonstrated that LAM cells recruit LECs and promote tube formation via VEGF-D/VEGFR3. Rapamycin only partially blocked this interaction. The synergistic effects of rapamycin and VEGFR3 inhibitors suggest a novel strategy for the treatment of LAM and other TSC2-mutated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Be…
- State Key Laboratory of Common Mechanism Research for Major Diseases, Haihe Laboratory of Cell Ecosystem, Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Me…
Zitieren
APA
Wang, H., Hu, D., Cheng, C., Zhang, X., Liu, J., Tian, X., Zhang, H., & Xu, K. F. (2025). Synergistic effects of mTOR inhibitors with VEGFR3 inhibitors on the interaction between TSC2-mutated cells and lymphatic endothelial cells. Science China Life Sciences. https://doi.org/10.1007/s11427-024-2760-4
Vancouver
Wang H, Hu D, Cheng C, Zhang X, Liu J, Tian X, et al. Synergistic effects of mTOR inhibitors with VEGFR3 inhibitors on the interaction between TSC2-mutated cells and lymphatic endothelial cells. Science China Life Sciences. 2025. doi:10.1007/s11427-024-2760-4
BibTeX
@article{Wang2025,
author = {Wang, Hanghang and Hu, Danjing and Cheng, Chongsheng and Zhang, Xiaoxin and Liu, Junya and Tian, Xinlun and Zhang, Hongbing and Xu, Kai-Feng},
title = {Synergistic effects of mTOR inhibitors with VEGFR3 inhibitors on the interaction between TSC2-mutated cells and lymphatic endothelial cells},
journal = {Science China Life Sciences},
year = {2025},
doi = {10.1007/s11427-024-2760-4}
}
EUVIMED